The more important thing is the series of 10 or so papers from Lilly ( IIRC, you can check pubmed ) showing a progressively expanding role for AMPA in depression. There was a startling problem with SSRI MOA and time to clinical effect that everyone had to gloss over. These kind of "subtle" problems are opportunities for emerging technologies.
Nerdseeksblonde, Thanks for the article. I hadn't realized that blocking the NMDA receptor could *increase* the activity of the AMPA receptor. It would be interesting to find out more about that mechanism -
>>> "It turns out that blocking NMDA increases the activity of another receptor, AMPA, and that this boost in AMPA is crucial for ketamine’s rapid antidepressant actions." <<<
NPR Science Friday had a segment on that study that showed that ketamine can relieve depression in hours as opposed to to weeks for existing drugs. First few minutes of program are interesting. Side effects of ketamine include halucinations.
"Depression medication usually takes weeks to kick in. But one drug, ketamine, starts working in hours. In new research published this week in the journal Biological Psychiatry, scientists say they have a better idea of how the drug, also used as an anesthetic, may be affecting the brain. In this hour of Science Friday, guest host Joe Palca talks to the Director of the National Institute of Mental Health about what this drug reveals about depression and what it could mean for the future of depression treatment"
Market Data 
Markets 
AI
